Dovitinib (TKI-258, CHIR-258)

製品コードS1018

Dovitinib (TKI-258, CHIR-258)化学構造

分子量(MW):392.43

Dovitinib (TKI258, CHIR258)は一種の多ターゲットRTK阻害剤で、無細胞試験でIII型(FLT3/c-Kit)に作用する効果が一番強くて、このIC50値が1 nM/2 nMです。同時に、Dovitinib (TKI258, CHIR258)はIV型(FGFR1/3)とV型(VEGFR1-4) RTKsにも有効に作用して、IC50値が8-13 nMになりますが、InsR、EGFR、c-Met、EphA2、Tie2、IGF-1RとHER2に作用する効果が少し弱くなります。臨床4期。

サイズ 価格(税別)  
JPY 31722.00
JPY 28220.00
JPY 44820.00
JPY 78020.00

カスタマーフィードバック(7)

  • In vitro assays on CUX1-FGFR1-expressing Ba/F3 cells. a. IL-3 deprivation of Ba/F3 cells transduced with CUX1-FGFR1 resulted in transformation to growth factor independent growth. The mean growth ±SEM of three separate measurements over four consecutive days is presented. b. The dose-response curves of CUX1-FGFR1-transduced Ba/F3 cells, treated with TKI258 and PKC412 for 48 hours in the absence or presence of IL-3 (2 ng/ml) are presented. Points represent the average results of two experiments done in triplicate plotted with the curve-fitting GraphPad Prism 5 software; bars, SD. The calculated IC50 for each inhibitor is indicated. c. Western blot analyses of CUX1-FGFR1-transformed Ba/F3 cells after treatment with PKC412 and TKI258. Phosphorylation of CUX1-FGFR1 and its downstream effectors STAT5 and RPS6K decreased with increasing inhibitor concentrations. Expression of total CUX1-FGFR1, STAT5 and RPS6K remained unaffected. d. Effect of PKC412 and TKI258 on apoptosis of CUX1-FGFR1-expressing Ba/F3 cells after treatment for 48 hours. The percentage of apoptotic plus necrotic CUX1-FGFR1-transduced Ba/F3 cells is indicated.

    haematologica 2011 96, 922-926. Dovitinib (TKI-258, CHIR-258) purchased from Selleck.

    RT112 cells were exposed to PD173074 (PD) (500 nM) for 0-24 h, TKI-258 (TK) (500 nM) or SU5402 (SU) (5 nM) for 1 h. Cells were lysed, FGFR3 was immunoprecipitated (immunoprecipitated, IP) and blots (immunoblot, IB) were probed for phospho-tyrosine and reprobed for FGFR3 or probed for phospho-ERK and reprobed for total ERK.

    Brit J Cancer 2010 104, 75-82. Dovitinib (TKI-258, CHIR-258) purchased from Selleck.

  • Cells were exposed to PD173074 or TKI-258 (500 nM) for 24 h. Cell cycle profile was analysed using the Guava Easycyte Plus flow cytometry system.

    Brit J Cancer 2010 104, 75-82. Dovitinib (TKI-258, CHIR-258) purchased from Selleck.

     

    Orthotopic xenografts of HNSCC cell lines (A) SCC-1 and (B) OSC-19 were treated with dovitinib (20 mg/kg/day). In addition, the OSC-19 xenografts were treated with +/ radiation therapy. Marker, mean for triplicate; bars, SE. Statistical significance by unpaired t-test, p < 0.05.

    Oral Oncol 2012 48, 1242-9. Dovitinib (TKI-258, CHIR-258) purchased from Selleck.

  • Treatments were initiated at time of orthotopic implantation. Growth stabilization was seen by day 8 of treatment (Fig. B). On day 17, tumors were har-vested and histological analysis was performed (Fig. C). Following Ki67 staining, tumors from control xenografts were found to have a higher percentage of proliferating cells (62%) compared to those treated with dovitinib (14%; p = 0.005). The incidence of lymph nodes metastasis was greater in the control cohort ( n = 15) com-pared to those treated with dovitinib (n = 5).

    Oral Oncol 2012 48, 1242-9. Dovitinib (TKI-258, CHIR-258) purchased from Selleck.

    Dose–response curves for HNSCC cells and fibroblasts treated in vitro with dovitinib (0–1000 nM). Boxes, mean for triplicate; bars, SE

    Oral Oncol 2012 48, 1242-9. Dovitinib (TKI-258, CHIR-258) purchased from Selleck.

  • Ba/F3 cell lines expressing the recombinant TEL/kinase domain fusion protein for FGFR1-4 .Cells were grown in RPMI 1640 containing 10% FBS and 500 ng/mL puromycin. The parental Ba/F3 cell line transduced with an empty vector was grown in 10 ng/mL IL-3 (R & D systems). Cell viability was assessed at 72 hours using the Cell Titer 96 Aqueous One Solution (Promega). Data were plotted as percent viability relative to vehicle-treated cells and are shown as mean (±SD) from 3 experiments.

    AACR 2011 Dovitinib (TKI-258, CHIR-258) purchased from Selleck.

製品安全説明書

FLT3阻害剤の選択性比較

生物活性

製品説明 Dovitinib (TKI258, CHIR258)は一種の多ターゲットRTK阻害剤で、無細胞試験でIII型(FLT3/c-Kit)に作用する効果が一番強くて、このIC50値が1 nM/2 nMです。同時に、Dovitinib (TKI258, CHIR258)はIV型(FGFR1/3)とV型(VEGFR1-4) RTKsにも有効に作用して、IC50値が8-13 nMになりますが、InsR、EGFR、c-Met、EphA2、Tie2、IGF-1RとHER2に作用する効果が少し弱くなります。臨床4期。
ターゲット
FLT3 [1]
(Cell-free assay)
c-Kit [1]
(Cell-free assay)
FGFR1 [1]
(Cell-free assay)
VEGFR3/FLT4 [1]
(Cell-free assay)
FGFR3 [1]
(Cell-free assay)
1 nM 2 nM 8 nM 8 nM 9 nM
体外試験

Dovitinib potently inhibits the FGF-stimulated growth of WT and F384L-FGFR3-expressing B9 cells with IC50 of 25 nM. In addition, Dovitinib inhibits proliferation of B9 cells expressing each of the various activated mutants of FGFR3. Interestingly, there are minimal observed differences in the sensitivity of the different FGFR3 mutations to Dovitinib, with the IC50 ranging from 70 to 90 nM for each of the various mutations. IL-6-dependent B9 cells containing vector only (B9-MINV cells are resistant to the inhibitory activity of Dovitinib at concentrations up to 1 μM. Dovitinib inhibits cell proliferation of KMS11 (FGFR3-Y373C), OPM2 (FGFR3-K650E), and KMS18 (FGFR3-G384D) cells with IC50 of 90 nM (KMS11 and OPM2) and 550 nM, respectively. Dovitinib inhibits FGF-mediated ERK1/2 phosphorylation and induces cytotoxicity in FGFR3-expressing primary MM cells. BMSCs does confer a modest degree of resistance with 44.6% growth inhibition for cells treated with 500 nM Dovitinib and cultured on stroma compared with 71.6% growth inhibition for cells grown without BMSCs. Dovitinib inhibits proliferation of M-NFS-60, an M-CSF growth-driven mouse myeloblastic cell line with a median effective concentration (EC50) of 220 nM. [1] Treatment of SK-HEP1 cells with Dovitinib results in a dose-dependent reduction in cell number and G2/M phase arrest with reduction in the G0/G1 and S phases, inhibition of anchorage-independent growth and blockage of bFGF-induced cell motility. The IC50 for Dovitinib in SK-HEP1 cells is approximately 1.7 μM. Dovitinib also significantly reduces the basal phosphorylation levels of FGFR-1, FGFR substrate 2α (FRS2-α) and ERK1/2 but not Akt in both SK-HEP1 and 21-0208 cells. In 21-0208 HCC cells, Dovitinib significantly inhibits bFGF-induced phosphorylation of FGFR-1, FRS2-α, ERK1/2 but not Akt. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SupB15 NFXWUHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTBwNES5JO69VQ>? NFPt[ZczPTJyMkC3Ny=>
SupB15-R NFzvRVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\6cWlEPTB;MD61OVgh|ryP MUGyOVIxOjB5Mx?=
BaF3-pSRα NEP5SXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3:1Z2lEPTB;MD62Olgh|ryP MnW4NlUzODJyN{O=
BaF3-p210Bcr-Abl NX[xcmNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTBwNkmyJO69VQ>? M4j4bFI2OjB{MEez
BaF3-p210Bcr-Abl-T315I MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIq1S29KSzVyPUKuOlI3KM7:TR?= M1WwRlI2OjB{MEez
CCRF-CEM M3;u[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HrVmlEPTB;MD6zPVgh|ryP NXnqRXVXOjV{MEKwO|I>
CEM/C2 MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzEXXltUUN3ME2xMlEzPSEQvF2= NELTflMzPTJyMkC3Ni=>
Nalm-6 M{DBZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1j2SGlEPTB;MD6zPFIh|ryP MXiyOVIxOjB5Mh?=
SEM-K2 M1zTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTBwMEKyJO69VQ>? M3fneFI2OjB{MEey
HB-1119 NFLxRoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTBwMEK4JO69VQ>? M1:yZlI2OjB{MEey
RS4:11 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLPTWM2OD1{LkixJO69VQ>? MoDpNlUzODJyN{K=
Nalm-6 MoT5RZBweHSxc3nzJGF{e2G7 NYjKZZZUOiEQvF2= NHOxWJIzPC92ODDo MlrCbY5lfWOnczDhdI9xfG:|aYOgdoV{fWy2aX7nJIlvKGGkb4X0JFczLSCxZjDj[YxtKGSnYYToJIFnfGW{IEK0JIghfHKnYYTt[Y51KGGwZDC4NUUh[W[2ZYKgOFghcA>? MXeyOVIxOjB5Mh?=
SEM-K2 MmC1RZBweHSxc3nzJGF{e2G7 NVu1TVJ7OC5zL{Gg{txO NVrUSVZ[OjRiaB?= M2Xub4lv\HWlZYOg[YFzdHliYYDvdJRwe2m|IH;mJHNGVS2NMjDj[YxteyCjdDCwMlEh|ryPIHHmeIVzKDJ2IHi= NWi5UJFpOjV{MEKwO|I>
HCT-116 NVjvcmQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTrTWM2OD1|LkC1NE42QCEQvF2= NIPl[nUzPDR7NUe1NC=>
HT-29 MlfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVi4[VBwUUN3ME21MlIyNjl|IN88US=> MWGyOFQ6PTd3MB?=
SW-480 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Prd2lEPTB;ND6zN|AvPDdizszN NWn3PJVJOjR2OUW3OVA>
CaCO2 NYLkeXlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzvempKSzVyPUOuNlMxNjZ2IN88US=> MUSyOFQ6PTd3MB?=
LS174T MkPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXkTWM2OD12LkOzNE41PyEQvF2= MlXhNlQ1QTV5NUC=
HEC-1A NYmxPY9iTnWwY4Tpc44hSXO|YYm= NE[5dlcxNjB3L{CuNU8xNjVizszN NYfWdnVTPzJiaB?= NH3wcHVk[XW|ZYOgZUBl\WO{ZXHz[UBqdiCVVFHUN{whTVKNLDDhcoQhSUuWIIDoc5NxcG:{eXzheIlwdg>? M2TIXlI1PDl3N{Ww
AN3CA M2LsW2Z2dmO2aX;uJGF{e2G7 MXuwMlA2NzBwMT:wMlUh|ryP NY[0N41pPzJiaB?= NXfZe2ZL[2G3c3XzJIEh\GWlcnXhd4UhcW5iU2TBWFMtKEWUSzygZY5lKEGNVDDwbI9{eGixconsZZRqd25? NFO5UZAzPDR7NUe1NC=>
MFE-296  M{H6[mZ2dmO2aX;uJGF{e2G7 NVPubVFOOC5yNT:wMlEwOC53IN88US=> MnnDO|IhcA>? NHS4VZhk[XW|ZYOgZUBl\WO{ZXHz[UBqdiCVVFHUN{whTVKNLDDhcoQhSUuWIIDoc5NxcG:{eXzheIlwdg>? MlT5NlQ1QTV5NUC=
UMC3 NUGxXoFoS2WubDDWbYFjcWyrdImgRZN{[Xl? Mn30NU0yOCEQvF2= NF;ScJI4OiCq MXXpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M2\MTVI1OzJ3NE[x
5637 M13oOGNmdGxiVnnhZoltcXS7IFHzd4F6 NE\XT5kyNTFyIN88US=> MlTtO|IhcA>? M1HDVIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M3XuSVI1OzJ3NE[x
HU456 M3fzRmNmdGxiVnnhZoltcXS7IFHzd4F6 NGn2bm8yNTFyIN88US=> MkDkO|IhcA>? NG\NfGJqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NGrZV4wzPDN{NUS2NS=>
MGHU4 MXrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MoPBNU0yOCEQvF2= NVLENpU4PzJiaB?= MmXGbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NIKzb3UzPDN{NUS2NS=>
HT1376 NFS0SYtE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MlzsNU0yOCEQvF2= MkXOO|IhcA>? M3zvXYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MmTkNlQ{OjV2NkG=
RT112 NFHk[|hE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NI\weWYyNTFyIN88US=> M2LJcFczKGh? MYLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MVWyOFMzPTR4MR?=
T24 NXLZWWdLS2WubDDWbYFjcWyrdImgRZN{[Xl? NUDtVZl2OS1zMDFOwG0> MUS3NkBp M1vrU4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NUTkN5oxOjR|MkW0OlE>
BFTC905 M3ziR2NmdGxiVnnhZoltcXS7IFHzd4F6 MlGxNU0yOCEQvF2= NX;3e4pWPzJiaB?= MkXibY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NHnyOJUzPDN{NUS2NS=>
TCC-SUP M4DRSmNmdGxiVnnhZoltcXS7IFHzd4F6 NEPZ[2wyNTFyIN88US=> NF:xW404OiCq MmfwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> M3\aelI1OzJ3NE[x
RT4 M1;GT2NmdGxiVnnhZoltcXS7IFHzd4F6 NH\zcHgyNTFyIN88US=> M3PqT|czKGh? MV3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NVeyeGlsOjR|MkW0OlE>
HONE1 M{fOfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVuwMlEuOTBizszN NFnHWnk1QMLiaB?= Mnu4bY5lfWOnczDHNk9OKGSnbHH5JIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy MWCyOFI{QDB7NB?=
HNE1 M3jQVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXxNE4yNTFyIN88US=> NHXBSWk1QMLiaB?= MVHpcoR2[2W|IFeyM20h\GWuYYmgbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= NUnpSXRlOjR{M{iwPVQ>
CNE2  MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHv5d40xNjFvMUCg{txO M3XT[|Q5yqCq NUThXWVRcW6mdXPld{BIOi:PIHTlcIF6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz M1;mZVI1OjN6MEm0
C666-1 NFHqVXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWmwMlEuOTBizszN MnjTOFjDqGh? NEHoTVFqdmS3Y3XzJGczN01iZHXsZZkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NUTuOYg1OjR{M{iwPVQ>
HeLa MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVWwMlEuOTBizszN NX2x[m4xOjRiaB?= MWLpcoR2[2W|IFeyM20h[XK{ZYP0JIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy MmnjNlQzOzhyOUS=
Hep3B NH62dW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnld4hrOC5zLUGwJO69VQ>? NFvHRmgzPCCq M2HhSIlv\HWlZYOgS|LDqGG{cnXzeOKh MUGyOFI{QDB7NB?=
HepG2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnieGg1QCCq NFHrb3VKSzVyPUKuO|I4KMLzIECuOFI6KM7:TR?= M{fQW|I{PTR4NUmx
Hep3B MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\oTFVVPDhiaB?= M2nOUmlEPTB;ND6yNlMhyrFiMD64N|kh|ryP MYKyN|U1PjV7MR?=
PLC/PRF5 NYfmeoZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13M[FQ5KGh? MVTJR|UxRTF4LkGyNEDDuSB2LkCwNUDPxE1? M2LGW|I{PTR4NUmx
Huh7 NXTtSotDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\YOFghcA>? Mn;hTWM2OD1zNT6wNFchyrFiNz6zN|Qh|ryP MkXVNlM2PDZ3OUG=
HepG2 M1T4WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mln0O|IhcA>? M4HDWmlEPTB;MT6yNFAhyrFiMD6yNlYh|ryP NXr0bXNxOjN3NE[1PVE>
Hep3B MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2j5ZVczKGh? MWfJR|UxRTBwOEmyJOKyKDBwMES0JO69VQ>? NYTK[VRXOjN3NE[1PVE>
PLC/PRF5 M2rtNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTVe5BQPzJiaB?= M{C2O2lEPTB;Mz6xNVAhyrFiMD6zN|ch|ryP MmPaNlM2PDZ3OUG=
Huh7 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[3NkBp M4focGlEPTB;Mz65PFAhyrFiMD64NFMh|ryP MVKyN|U1PjV7MR?=
MFE280 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{Twc2lEPTB;MD60NkDDuSByLkC2JO69VQ>? Mn7NNlM1PDN6MEW=
AN3CA NXzXV4ppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHmXoU1UUN3ME2wMlUxKMLzIECuNVAh|ryP NVnwNopROjN2NEO4NFU>
HEC155 NHHlbpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1v0[mlEPTB;MD62OkDDuSByLkC5JO69VQ>? M3XDbVI{PDR|OEC1
MFE296 NH;VSlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LtRWlEPTB;MD62OkDDuSByLkG5JO69VQ>? MXiyN|Q1OzhyNR?=
SPAC1S MmDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnnWHR6UUN3ME2wMlc4KMLzIECuNFgh|ryP NGKwXYczOzR2M{iwOS=>
RL952 M2O1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwOUOgxtEhOC5yMTFOwG0> NV\qV3RVOjN2NEO4NFU>
EN1 MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDrPY5wUUN3ME2xMlAzKMLzIECuNlUh|ryP M2PmVVI{PDR|OEC1
SNGII M{PzdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml24TWM2OD1zLkK0JOKyKDBwMkig{txO MoXTNlM1PDN6MEW=
ISHIKAWA MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTFwM{CgxtEhOC5zMTFOwG0> MnnqNlM1PDN6MEW=
HEC1A M3LSbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUG1SVQ2UUN3ME2xMlM1KMLzIECuN|Ah|ryP MlfGNlM1PDN6MEW=
KLE M4PibWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLpc286UUN3ME2xMlM4KMLzIECuNFIh|ryP M1T2cVI{PDR|OEC1
SNGM MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[ycokyUUN3ME2xMlQzKMLzIECuNVMh|ryP MX:yN|Q1OzhyNR?=
USPC2 M1HRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVSyVFdnUUN3ME2xMlYzKMLzIECuNFEh|ryP NFj6TJkzOzR2M{iwOS=>
EN NUGyfVhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXoXYNPUUN3ME2xMlY3KMLzIECuNFEh|ryP M2TNc|I{PDR|OEC1
MFE319 M1jqVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTqcnlPUUN3ME2xMlg4KMLzIECuOFUh|ryP M2LGVVI{PDR|OEC1
EFE184 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1juO2lEPTB;Mj6wOEDDuSByLkGzJO69VQ>? MmTVNlM1PDN6MEW=
ECC1 M4jtXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJwMEegxtEhOC5yMTFOwG0> MVmyN|Q1OzhyNR?=
HEC1B MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfSOXdKSzVyPUKuOVchyrFiMD6yN{DPxE1? MX2yN|Q1OzhyNR?=
USPC1 M3TtZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTJwNkCgxtEhOC5zMzFOwG0> NVH3c2xDOjN2NEO4NFU>
SPAC1L NYPlbWlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlz4TWM2OD1|LkC2JOKyKDFwMUSg{txO NUP5SolEOjN2NEO4NFU>
HUVEC NGrIOGNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1jobVAuOjVizszN M{Gz[FczKGh? Mon2SG1UVw>? M1[3eolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MmW5NlMzOjhyMUe=
HMVEC NWPaN|FQS2WubDDWbYFjcWyrdImgRZN{[Xl? NYTZdm1ZOC1{NTFOwG0> NVPJSVd7PzJiaB?= MYTEUXNQ M4P4WolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NH7hcpozOzJ{OECxOy=>
MHCC-97H MkP2R4VtdCCYaXHibYxqfHliQYPzZZk> M4rpTlAuOjVizszN NFS5VmU4OiCq NYTyXYw1TE2VTx?= NV3mNYoxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NWDHTJNUOjN{MkiwNVc>
SMMC7721 MnL1R4VtdCCYaXHibYxqfHliQYPzZZk> NE\RTIwxNTJ3IN88US=> NHTG[GY4OiCq NGHudWpFVVOR M2jwPIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MlTxNlMzOjhyMUe=
Huh-7 NH\yXI1CeG:ydH;zbZMhSXO|YYm= NIj6dJcxNTF{LkWg{txO NV\SWY8yOjRiaB?= NXXHcZhqTE2VT9Mg Mn:0d4Vve2m2aYrld{BJS0NiY3XscJMhfG9iVGLBTWwuKGGwZDD0bYdifHW8dX3hZk1qdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MnPINlIzOzB2N{m=
Sk-Hep1 NGr3XVhCeG:ydH;zbZMhSXO|YYm= NFm5XpgxNTF{LkWg{txO NGG2[XYzPCCq M4TaOmROW00EoB?= MX;z[Y5{cXSrenXzJGhESyClZXzsd{B1dyCWUlHJUE0h[W6mIITp[4F1fXq3bXHiMYlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NVjVPHROOjJ{M{C0O|k>
Hep3B MX;BdI9xfG:|aYOgRZN{[Xl? MWqwMVEzNjVizszN NIDrXFUzPCCq NXz0fopyTE2VT9Mg M176SJNmdnOrdHn6[ZMhUEOFIHPlcIx{KHSxIGTSRWlNNSCjbnSgeIlo[XS3eoXtZYIucW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M2DxelIzOjNyNEe5
PLC5 M2rxOWFxd3C2b4Ppd{BCe3OjeR?= M3S3[lAuOTJwNTFOwG0> MVSyOEBp NHTCUoZFVVORwrC= NFLzeVN{\W6|aYTpfoV{KEiFQzDj[YxteyC2bzDUVmFKVC1iYX7kJJRq\2G2dYr1cYFjNWmwZIXj[YQh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NGTURWIzOjJ|MES3PS=>
PLC5 Mlf2R4VtdCCYaXHibYxqfHliQYPzZZk> MW[wMVE2KM7:TR?= M1X1VlczKGh? NIjjVWpz\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{wrC= MYGyNlE5ODNyOB?=
Hep3B Ml7KR4VtdCCYaXHibYxqfHliQYPzZZk> NFuxbpQxNTF3IN88US=> MoD6O|IhcA>? M4nDe5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XMEoB?= MX[yNlE5ODNyOB?=
Sk-Hep1 NV3VPGQ4S2WubDDWbYFjcWyrdImgRZN{[Xl? M1fFXlAuOTVizszN MVe3NkBp NUW5SFZ7emWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg MnrCNlIyQDB|MEi=
Huh-7 NXL5T4hDS2WubDDWbYFjcWyrdImgRZN{[Xl? MXGwMVE2KM7:TR?= M{XXb|czKGh? NGq0TY1z\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{wrC= MYmyNlE5ODNyOB?=
PLC5 M2jIZWFxd3C2b4Ppd{BCe3OjeR?= NGXSXHoxNTF3IN88US=> MnjqNlQhcA>? MmTCbY5kemWjc3XzJIFxd3C2b4TpZ{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzyqB? NUToS29HOjJzOECzNFg>
Hep3B M4SwNGFxd3C2b4Ppd{BCe3OjeR?= MlfMNE0yPSEQvF2= NVezSWxxOjRiaB?= MV7pcoNz\WG|ZYOgZZBweHSxdHnjJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? M2rjVVIzOThyM{C4
Sk-Hep1 NH7nTJVCeG:ydH;zbZMhSXO|YYm= NVq0O5c4OC1zNTFOwG0> MkPNNlQhcA>? MUjpcoNz\WG|ZYOgZZBweHSxdHnjJINmdGxiZHXheIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>? MXmyNlE5ODNyOB?=
Huh-7 MlXERZBweHSxc3nzJGF{e2G7 NVG3U2hFOC1zNTFOwG0> NH7RenYzPCCq Mk\zbY5kemWjc3XzJIFxd3C2b4TpZ{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzyqB? Ml;TNlIyQDB|MEi=
PLC5 NVroelM{TnWwY4Tpc44hSXO|YYm= Mn7ZNE0yOCEQvF2= M{Kwd|I1KGh? MXzjZZV{\XNiZH;z[U1l\XCnbnTlcpQhTE6DIH\yZYdu\W62YYTpc44> M4DGclIzOThyM{C4
Hep3B M1mzSGZ2dmO2aX;uJGF{e2G7 MVWwMVExKM7:TR?= NVrORWYzOjRiaB?= MUHjZZV{\XNiZH;z[U1l\XCnbnTlcpQhTE6DIH\yZYdu\W62YYTpc44> M1;zUVIzOThyM{C4
Sk-Hep1 Mn;XSpVv[3Srb36gRZN{[Xl? M3O4NVAuOTBizszN MknXNlQhcA>? NXjOSZlM[2G3c3XzJIRwe2VvZHXw[Y5l\W62IFTORUBnemGpbXXueIF1cW:w Mnu1NlIyQDB|MEi=
Huh-7 MkLwSpVv[3Srb36gRZN{[Xl? MWewMVExKM7:TR?= NIjERm4zPCCq MVrjZZV{\XNiZH;z[U1l\XCnbnTlcpQhTE6DIH\yZYdu\W62YYTpc44> M3fG[lIzOThyM{C4
SW780 NXPqV5JWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLkOUBl M{TFW2lEPTB;NUCgcm0> NHXwWowzOTFzOU[2NS=>
RT112 NXvpZ2g5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoXCOUBl NG\lPHFKSzVyPUG1JI5O MnPKNlEyOTl4NkG=
RT4 NFjWfolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1flbFUh\A>? MoTOTWM2OD13IH7N MUSyNVEyQTZ4MR?=
JMSU1 MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnq4OUBl Mo\vTWM2OD13MDDuUS=> M1nFcVIyOTF7Nk[x
J82 MnLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPLOUBl MVfJR|UxRTF2MECgcm0> MnGzNlEyOTl4NkG=
97-7 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXK1JIQ> M1HKbWlEPTB;MUCwNEBvVQ>? MXiyNVEyQTZ4MR?=
RT112 MnK2SpVv[3Srb36gRZN{[Xl? NWruPHVqPTByIH7N M3jFN|I1KGh? M33wfIlv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBk\WyuczDpckBIOcLiYXPjc41x[W6rZXSgZpkh[SCmZXPy[YF{\SCrbjDTJIFv\CCJMj;NJJBp[XOncx?= NVy4UnN1OjFzMUm2OlE>
RT4 MkTaSpVv[3Srb36gRZN{[Xl? NEPHT5c2ODBibl2= MnLxNlQhcA>? MVPpcoNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gZ4VtdHNiaX6gS|HDqGGlY3;tdIFvcWWmIHL5JIEh\GWlcnXhd4UhcW5iUzDhcoQhTzJxTTDwbIF{\XN? NYTud2t1OjFzMUm2OlE>
MGH-U3 NEjYTJNHfW6ldHnvckBCe3OjeR?= NI[0XZA2ODBibl2= MnzZNlQhcA>? NY\2Ull7cW6lcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGOnbHzzJIlvKEdzwrDhZ4NwdXCjbnnl[EBjgSCjIHTlZ5Jm[XOnIHnuJHMh[W6mIFeyM20heGijc3Xz MmHoNlEyOTl4NkG=
SW780 M1G5NWZ2dmO2aX;uJGF{e2G7 M2HlWVUxOCCwTR?= NYL6VWp[OjRiaB?= NF3jW3pqdmO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[2WubIOgbY4hTzIEoHHjZ49ueGGwaXXkJIJ6KGFiZHXjdoVie2ViaX6gV{BidmRiR{KvUUBxcGG|ZYO= Mo\MNlEyOTl4NkG=
97-7 M2fzb2Z2dmO2aX;uJGF{e2G7 NYP5cVhkPTByIH7N NXPHNm1FOjRiaB?= M{nIWYlv[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBk\WyuczDpckBIOcLiYXPjc41x[W6rZXSgZpkh[SCmZXPy[YF{\SCrbjDTJIFv\CCJMj;NJJBp[XOncx?= MUmyNVEyQTZ4MR?=
 J807C NXjFNodiS2WubDDWbYFjcWyrdImgRZN{[Xl? NGrlR3oxNTRyMDDuUS=> NYfXTHg{PDhiaB?= NXL4bnZUcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MUixOVU6QDhzNB?=
Y373C MXzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUXL[5dEOC12MECgcm0> NGjyW|Q1QCCq NWDlU3JHcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M2rUNlE2PTl6OEG0
K650E NGDj[4hE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NY\FSIRbOC12MECgcm0> NWPZXmpZPDhiaB?= NVTJbmtncW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MoL5NVU2QTh6MUS=
G384D MmrKR4VtdCCYaXHibYxqfHliQYPzZZk> NXjFc2xXOC12MECgcm0> MVK0PEBp NH3wWndqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MWSxOVU6QDhzNB?=
F384L MYfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NX3leJF{OC12MECgcm0> NYTueIpoPDhiaB?= NH\6W3hqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M{HTUVE2PTl6OEG0
KMS11 Mk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLNT3R2PzJiaB?= MYPJR|UxRTlyIH7N MojyNVU2QTh6MUS=
KMS18 NIXyVW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\GO|IhcA>? M1;mR2lEPTB;NUWwJI5O Mo[4NVU2QTh6MUS=
OPM2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzq[m84OiCq NXz0dGlVUUN3ME25NEBvVQ>? NH7JPHkyPTV7OEixOC=>
H929 MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjXTJJpPzJiaB?= M2W1e2lEPTB-IEK1NFAhdk1? NUG4WY92OTV3OUi4NVQ>
8226 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrYXIJCPzJiaB?= NF7SdYNKSzVyPjCyOVAxKG6P M{HwWlE2PTl6OEG0
U266 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYK3NkBp NEL4bpRKSzVyPjCyOVAxKG6P MnjVNVU2QTh6MUS=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Dovitinib induces both cytostatic and cytotoxic responses in vivo resulting in regression of FGFR3-expressing tumors.[1] Dovitinib shows a dose- and exposure-dependent inhibition of target receptor tyrosine kinases (RTKs) expressed in tumor xenografts. Dovitinib potently inhibits tumor growth of six HCC lines. Inhibition of angiogenesis correlated with inactivation of FGFR/PDGFRβ/VEGFR2 signaling pathways. In an orthotopic model, Dovitinib potently inhibits primary tumor growth and lung metastasis and significantly prolonged mouse survival. [2] Administration of Dovitinib results in significant tumor growth inhibition and tumor regressions, including large, established tumors (500-1,000 mm3). [3]

お薦めの試験操作(参考用のみ)

キナーゼ試験:[1]
+ 展開

In vitro kinase assays:

The inhibitory concentration of 50% (IC50) values for the inhibition of RTKs by Dovitinib are determined in a time-resolved fluorescence (TRF) or radioactive format, measuring the inhibition by Dovitinib of phosphate transfer to a substrate by the respective enzyme. The kinase domains of FGFR3, FGFR1, PDGFRβ, and VEGFR1-3 are assayed in 50 mM HEPES (N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid), pH 7.0, 2 mM MgCl2, 10 mM MnCl2 1 mM NaF, 1 mM dithiothreitol (DTT), 1 mg/mL bovine serum albumin (BSA), 0.25 μM biotinylated peptide substrate (GGGGQDGKDYIVLPI), and 1 to 30 μM adenosine triphosphate (ATP) depending on the Km for the respective enzyme. ATP concentrations are at or just below Km. For c-KIT and FLT3 reactions the pH is raised to 7.5 with 0.2 to 8 μM ATP in the presence of 0.25 to 1 μM biotinylated peptide substrate (GGLFDDPSYVNVQNL). Reactions are incubated at room temperature for 1 to 4 hours and the phosphorylated peptide captured on streptavidin-coated microtiter plates containing stop reaction buffer (25 mM EDTA [ethylenediaminetetraacetic acid], 50 mM HEPES, pH 7.5). Phosphorylated peptide is measured with the DELFIA TRF system using a Europium-labeled antiphosphotyrosine antibody PT66. The concentration of Dovitinib for IC50 is calculated using nonlinear regression with XL-Fit data analysis software version 4.1 (IDBS). Inhibition of colony-stimulating factor-1 receptor (CSF-1R), PDGFRα, insulin receptor (InsR), and insulin-like growth factor receptor 1 (IGFR1) kinase activity is determined at ATP concentrations close the Km for ATP.
細胞試験: [1]
+ 展開
  • 細胞株: B9 cells, MM cell lines
  • 濃度: 100 nM
  • 反応時間: 48-96 hours
  • 実験の流れ: Cell viability is assessed by 3-(4,5-dimethylthiazol)-2,5-diphenyl tetrazolium (MTT) dye absorbance. Cells are seeded in 96-well plates at a density of 5 × 103 (B9 cells) or 2 × 104 (MM cell lines) cells per well. Cells are incubated with 30 ng/mL aFGF and 100 μg/mL heparin or 1% IL-6 where indicated and increasing concentrations of Dovitinib. For each concentration of Dovitinib, 10 μL aliquots of drug or DMSO diluted in culture medium is added. For drug combination studies, cells are incubated with 0.5 μM dexamethasone, 100 nM Dovitinib, or both simultaneously where indicated. To evaluate the effect of Dovitinib on growth of MM cells adherent to BMSCs, 104 KMS11 cells are cultured on BMSC-coated 96-well plates in the presence or absence of Dovitinib. Plates are incubated for 48 to 96 hours. For assessment of macrophage colony-stimulating factor (M-CSF)-mediated growth, 5 × 103 M-NFS-60 cells/well are incubated with serial dilutions of Dovitinib with 10 ng/mL M-CSF and without granulocyte-macrophage colony-stimulating factor (GM-CSF). After 72 hours cell viability is determined using Cell Titer-Glo Assay. Each experimental condition is performed in triplicate.
    (参考用のみ)
動物試験:[1]
+ 展開
  • 動物モデル: 8-week-old female BNX mice bearing KMS11 cells
  • 製剤: 5 mM citrate buffer
  • 投薬量: 10, 30, or 60 mg/kg
  • 投与方法: Gavage
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 30 mg/mL (76.44 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
30% PEG400+0.5% Tween80+5% propylene glycol
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 392.43
化学式

C21H21FN6O

CAS No. 405169-16-6
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01497392 Completed Adenocarcinoma of the Pancreas|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific Roswell Park Cancer Institute|National Cancer Institute (NCI)|Novartis March 29, 2012 Phase 1
NCT02048943 Withdrawn Duct Cell Adenocarcinoma of the Pancreas|Recurrent Pancreatic Cancer|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific Roswell Park Cancer Institute|National Cancer Institute (NCI)|Novartis March 2015 Phase 1
NCT02268435 Withdrawn Gastrointestinal Stromal Tumors Asan Medical Center March 2015 Phase 1
NCT02108782 Withdrawn Gastrinoma|Glucagonoma|Insulinoma|Pancreatic Polypeptide Tumor|Recurrent Islet Cell Carcinoma|Somatostatinoma Academic and Community Cancer Research United|National Cancer Institute (NCI) October 2014 Phase 2
NCT02116803 Completed Solid Tumors Novartis Pharmaceuticals|Novartis May 2014 Phase 2|Phase 3
NCT01994590 Active, not recruiting Prostate Cancer M.D. Anderson Cancer Center|Novartis May 2014 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

Related Antibodies

FLT3信号経路図

FLT3 Inhibitors with Unique Features

相関FLT3製品

Tags: Dovitinib (TKI-258, CHIR-258)を買う | Dovitinib (TKI-258, CHIR-258) ic50 | Dovitinib (TKI-258, CHIR-258)供給者 | Dovitinib (TKI-258, CHIR-258)を購入する | Dovitinib (TKI-258, CHIR-258)費用 | Dovitinib (TKI-258, CHIR-258)生産者 | オーダーDovitinib (TKI-258, CHIR-258) | Dovitinib (TKI-258, CHIR-258)化学構造 | Dovitinib (TKI-258, CHIR-258)分子量 | Dovitinib (TKI-258, CHIR-258)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID